Fig. 1.

Characterization of MSLN TRuC-T cells expressing a chimeric PD1-CD28 receptor. a Lentiviral constructs containing the MH1 anti-mesothelin TRuC (TC-210), or with a bi-cistronic construct containing the anti-mesothelin TRuC followed by a sequence encoding the PD1-CD28 CSR with the transmembrane region of either PD-1 (PD1TM) or CD28 (CD28TM). b Coexpression of PD-1 and the TRuC receptor in T cells at Day 10 of expansion. c Percent transduction of CD3⁺ T cells as measured by TRuC receptor expression. d MFI of TRuC receptor expression of TRuC⁺ T cells. e MFI of PD-1 expression of TRuC⁺ T cells. f Frequency of CD8⁺ and CD4⁺ T cells TRuC⁺ T cells on Day 10 of process. Data were analyzed for statistical significance by two-way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Data shown are from a single experiment representing nine donors. CD cluster of differentiation, CSR chimeric switch receptor, ECD extracellular domain, ICD intracellular domain, LTR long terminal repeat, MFI median florescence intensity, MSLN mesothelin, NT nontransduced, PD-1 programmed cell death protein 1, TRuC T cell receptor fusion construct, TMD transmembrane domain